Inactive Instrument

Press Releases Oncology Venture A/S Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

Jun. 25	Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	CI
May. 24	Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance	Jun. 27	AQ
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer	Jun. 25	AQ
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement	May. 20	AQ
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances	May. 14	AQ
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock	May. 07	AQ
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1	May. 06	AQ
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer	May. 02	AQ
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement	Apr. 29	AQ
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)	Apr. 17	AQ
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split	Apr. 04	AQ
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	Mar. 27	AQ
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)	Mar. 25	AQ
Allarity Therapeutics : Material Agreement - Form 8-K	Mar. 20	PU
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update	Mar. 08	AQ
Allarity Therapeutics to Present at Biomarkers 2024	Feb. 28	AQ
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor	Dec. 12	AQ
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic	Dec. 06	AQ
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic	Dec. 05	AQ
Allarity Therapeutics to Present at Biomarkers Europe 2023	23-10-02	AQ
Allarity Therapeutics : Modification to Rights of Security Holders - Form 8-K	23-09-27	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncology Venture A/S Nasdaq Stockholm

Equities

Press Releases

Filters